NeuroOne Medical Technologies (NASDAQ:NMTC) Earns Buy Rating from Analysts at JonesTrading

JonesTrading began coverage on shares of NeuroOne Medical Technologies (NASDAQ:NMTC) in a research note issued to investors on Monday, MarketBeat.com reports. The brokerage issued a buy rating and a $1.50 price target on the stock.

NMTC has been the subject of several other reports. Zacks Research raised shares of NeuroOne Medical Technologies from a “hold” rating to a “strong-buy” rating in a report on Monday, January 5th. Wall Street Zen upgraded shares of NeuroOne Medical Technologies to a “sell” rating in a research note on Saturday, February 21st. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $1.98.

NeuroOne Medical Technologies Trading Down 2.5%

Shares of NASDAQ NMTC opened at $0.79 on Monday. The company has a market capitalization of $39.92 million, a price-to-earnings ratio of -4.65 and a beta of 0.74. NeuroOne Medical Technologies has a twelve month low of $0.40 and a twelve month high of $1.16. The business has a 50 day simple moving average of $0.81 and a 200-day simple moving average of $0.79.

NeuroOne Medical Technologies (NASDAQ:NMTC) last released its quarterly earnings data on Tuesday, February 17th. The company reported ($0.03) EPS for the quarter, topping analysts’ consensus estimates of ($0.04) by $0.01. NeuroOne Medical Technologies had a negative net margin of 78.34% and a negative return on equity of 119.92%. The firm had revenue of $2.89 million during the quarter, compared to the consensus estimate of $2.47 million.

Insider Buying and Selling at NeuroOne Medical Technologies

In other news, insider David J. Wambeke acquired 1,000,000 shares of the business’s stock in a transaction that occurred on Sunday, March 1st. The shares were purchased at an average cost of $0.67 per share, for a total transaction of $670,000.00. Following the transaction, the insider directly owned 1,000,000 shares in the company, valued at $670,000. This trade represents a ∞ increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 8.90% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the company. Focus Financial Network Inc. acquired a new stake in shares of NeuroOne Medical Technologies in the third quarter valued at approximately $31,000. Warberg Asset Management LLC bought a new position in NeuroOne Medical Technologies in the 2nd quarter worth approximately $27,000. Legato Capital Management LLC acquired a new stake in NeuroOne Medical Technologies in the 4th quarter valued at approximately $34,000. Squarepoint Ops LLC bought a new stake in NeuroOne Medical Technologies during the 4th quarter valued at $36,000. Finally, Susquehanna International Group LLP acquired a new position in NeuroOne Medical Technologies during the 3rd quarter worth $47,000. Institutional investors own 16.07% of the company’s stock.

About NeuroOne Medical Technologies

NeuroOne Medical Technologies Corp. is a medical device company focused on developing advanced neural interface technologies for diagnostic and therapeutic applications in neurosurgery and neurology. The company’s core mission is to improve patient outcomes through next-generation electrode systems that enable high-resolution neural recording and targeted stimulation. By leveraging proprietary thin-film microelectrode arrays, NeuroOne aims to offer clinicians unprecedented single-unit precision during brain mapping procedures.

The company’s flagship platform, the EVO™ system, integrates thin-film neural electrodes with intraoperative monitoring hardware and software.